Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Treatment outcome of Malaysian patients with advanced lung adenocarcinoma

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

Chee Chai

Citation

Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532

Authors

C.S. Chai, C.K. Liam, Y.K. Pang, K.S. Kow, C.K. Wong, M.E. Poh, J.L. Tan

Author affiliations

  • Department Of Medicine, Chest Division, University of Malaya Faculty of Medicine, 50603 - Kuala Lumpur/MY
More

Resources

Aim/Background

This study aimed to determine the progression-free survival (PFS), overall survival (OS), objective response rate (ORR) and disease control rate (DCR) in patients with locally advanced or metastatic lung adenocarcinoma treated with first-line epidermal growth factor receptor -tyrosine kinase inhibitor (EGFR-TKI) versus chemotherapy.

Methods

A retrospective cohort observational study of patients with locally advanced (stage IIIB) or metastatic (stage IV) lung adenocarcinoma treated with first-line EGFR-TKI or chemotherapy at University Malaya Medical Centre from 1st August 2010 to 31th July 2014.

Results

Of 117 patients with EGFR mutation-positive tumours, the median PFS (6.93 months) for those treated with first-line EGFR-TKI (n = 98) was significantly longer than the median PFS (2.23 months) for those treated with first-line chemotherapy (n = 19) (HR, 0.50; 95% CI, 0.29 - 0.84; p = 0.010). The median OS was similar [10.40 months for first-line EGFR-TKI versus 9.63 months for first-line chemotherapy (HR, 0.92; 95% CI, 0.49–1.73; p = 0.797)]. The ORR for first-line EGFR-TKI and first-line chemotherapy was 42.9% and 10.5%, respectively (OR, 6.38; 95% CI, 1.40–39.11; p = 0.017) while the DCR was 79.6% and 36.8%%, respectively (OR, 6.69; 95% CI, 2.33–19.19; p < 0.001). Of 101 patients with EGFR mutation-negative tumours, the median PFS (2.93 months) and OS (10.43 months) for those treated with first-line chemotherapy (n = 85) was better than the median PFS (1.03 months) and OS (1.07 months) for those treated with first-line EGFR-TKI (n = 16) (HR for disease progression, 0.44; 95% CI, 0.25 - 0.77; p = 0.004; HR for death, 0.24; 95% CI, 0.12 - 0.77; p < 0.001). The ORR and DCR for first-line chemotherapy was 16.5% and 51.8%, respectively. No patient responded or had disease stabilisation with first-line EGFR-TKI.

Conclusions

This study showed the superiority of first-line EGFR-TKI over chemotherapy in patients with EGFR mutation-positive locally advanced or metastatic lung adenocarcinoma in terms of PFS, ORR and DCR. On the other hand, patients with locally advanced or metastatic EGFR wild-type lung adenocarcinoma do not respond to first-line EGFR-TKI. They had poorer PFS and OS when treated with first-line EGFR-TKI compared to first-line chemotherapy.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings